Shane Ward Sells 1,664 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) Stock

Cidara Therapeutics, Inc. (NASDAQ:CDTX) COO Shane Ward sold 1,664 shares of Cidara Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total transaction of $36,541.44. Following the transaction, the chief operating officer now directly owns 14,674 shares in the company, valued at $322,241.04. This represents a 10.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cidara Therapeutics Stock Down 1.4 %

NASDAQ CDTX opened at $22.05 on Friday. The company has a market cap of $155.39 million, a PE ratio of -0.86 and a beta of 0.88. Cidara Therapeutics, Inc. has a 52 week low of $10.00 and a 52 week high of $28.42. The firm’s 50-day simple moving average is $22.17 and its two-hundred day simple moving average is $17.71.

Cidara Therapeutics (NASDAQ:CDTX) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($5.38) EPS for the quarter, missing the consensus estimate of ($5.28) by ($0.10). Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 69.64%. As a group, equities research analysts anticipate that Cidara Therapeutics, Inc. will post -8.74 EPS for the current year.

Institutional Investors Weigh In On Cidara Therapeutics

Several institutional investors have recently added to or reduced their stakes in CDTX. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Cidara Therapeutics during the fourth quarter valued at about $56,000. Point72 Asset Management L.P. bought a new stake in shares of Cidara Therapeutics during the fourth quarter valued at about $165,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Cidara Therapeutics during the fourth quarter valued at about $339,000. Jane Street Group LLC bought a new stake in shares of Cidara Therapeutics during the fourth quarter valued at about $342,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Cidara Therapeutics during the fourth quarter valued at about $419,000. 35.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on CDTX. WBB Securities lifted their price objective on shares of Cidara Therapeutics from $40.00 to $45.00 and gave the stock a “strong-buy” rating in a report on Thursday, December 5th. HC Wainwright lifted their price objective on shares of Cidara Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Citizens Jmp began coverage on shares of Cidara Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $46.00 price target on the stock. Citigroup began coverage on shares of Cidara Therapeutics in a report on Wednesday. They issued an “outperform” rating on the stock. Finally, Royal Bank of Canada began coverage on shares of Cidara Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $34.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $39.14.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.